WHERE THE EVIDENCE STANDS
Tirzepatide's pivotal programme reported weight reduction of about 22.5 % at 72 weeks in its first obesity trial, a benchmark the retatrutide programme is now compared against. A head-to-head Phase 3 trial of retatrutide versus tirzepatide (TRIUMPH-5) is active.
The 30 April 2026 FDA proposal to exclude tirzepatide from the 503B bulks list follows more than 320 adverse-event reports tied to compounded versions, according to reporting on the proposal.
ENTRIES ABOUT Tirzepatide · 2
PAPER
Reports in 2026 describe falling physical activity among people on GLP-1 drugs, claims-data signals on bone and joint conditions with long-term use, and one-year persistence nearly doubling since 2021.
REGULATION
A 30 April 2026 proposal would exclude the three GLP-1 drugs from the 503B bulks list, closing the outsourcing-facility route that opened during the shortage years.
SOURCES
- Drug Discovery News. GLP-1 agonist clinical pipeline 2026. 26 Jun 2026. News feature. https://www.drugdiscoverynews.com/glp-1-agonist-clinical-pipeline-2026-semaglutide-tirzepatide-and-what-s-in-phase-2-17286
- AJMC. Peptide regulation debate intensifies after FDA advisory panel's controversial vote. 25 Sep 2026. News feature. https://www.ajmc.com/view/peptide-regulation-debate-intensifies-after-fda-advisory-panel-s-controversial-vote
REVIEWED 5 Oct 2026 · NEXT REVIEW JAN 2027 · CORRECTIONS ARE LOGGED HERE